A large population-based cohort study has linked COVID-19 to increased risk of diabetes, adding to the evidence that SARS-CoV-2 infection may contribute to the development of the metabolic disorder.

Abbott announced financial results for the first quarter ended March 31, 2023.

The US Department of Health and Human Services' Biomedical Advanced Research Development Authority (BARDA) this week issued a solicitation for proposals for the research and development of immune assays to evaluate responses to COVID-19 vaccines.

The US Food and Drug Administration this week released its guidance document for developers of medical devices for COVID-19, including diagnostic tests, on how to transition from Emergency Use Authorization to full marketing and regulatory authorization.

DiaSorin said on Monday that its full-year 2022 revenues grew 10 percent year over year on "solid performance" across all its businesses.

Quest Diagnostics has introduced two Post-COVID-19 panels for consumers that offer information about lingering health issues associated with previous COVID-19 virus infections.

Supplies of laboratory reagents, testing components and transport media are expected to normalize in the first half of 2023, ending shortages that date back to early in the pandemic, according to the Food and Drug Administration.

DiaSorin said late Friday that it has nabbed US Food and Drug Administration 510(k) clearance for a molecular assay that differentiates between infections with the SARS-CoV-2 and influenza A and B viruses.

Cue Health Inc., a healthcare technology company, reported financial results for the fourth quarter and full-year 2022.

BioMérieux reported Wednesday that its fourth quarter revenues rose 11 percent year over year.